Selinexor for the treatment of recurrent or metastatic salivary gland tumors: Results from the GEMS-001 clinical trial.

Alberto Hernando-Calvo Eoghan R MaloneDaphne DayAmy PrawiraIlan WeinrebS Y Cindy YangHorace WongAngela RodriguezSarah JenningsAnneli EliasonLisa WangAnna SpreaficoLillian L SiuAaron R Hansen

Published in: Cancer medicine (2023)

Although tumor reduction was observed across participants, single agent selinexor anti-tumor activity was limited.

Keyphrases

clinical trial
small cell lung cancer
randomized controlled trial
study protocol
phase ii
double blind
combination therapy
phase iii